Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.32 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19860763 | 0.87 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL36167 | 0.83 | ALDH1A1 (0.51) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL21728885 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL22768279 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL8847172 | 0.80 | ALDH1A1 (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL14707201 | 0.79 | MEN1 (0.44) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL22710143 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL24011779 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL9762672 | 0.78 | ALDH1A1 (0.47) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 | |
| SCHEMBL19223247 | 0.78 | ALDH1A1 (0.51) | ALDH1A1CYP3A4CYP2C9CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-16 | — | — | US | disclosed |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | ALDH1A1 4813/4885CYP3A4 2771/4885CYP2C9 1200/4885 |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | ALDH1A1 4813/4885CYP3A4 2771/4885CYP2C9 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.